The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Increased renal plasma flow in long‐term enalapril treatment of hypertension
The renal effects of long‐term antihypertensive treatment with enalapril were evaluated in 34 subjects ( age , 53 yr ; range , 27 to 65 ) with mild , uncomplicated hypertension . After receiving placebo for 4 wk , subjects were r and omly assigned to groups receiving incremental doses of enalapril ( 10 , 20 , or 40 mg/day for 4 wk each ) in a single morning dose or two divided doses , or of placebo . One subject who received enalapril  developed acute renal failure by the end of the study . There was no evidence of glomerular or tubular damage in the other subjects ; as measured by 24‐hr urinary protein excretion , urinary activity of N‐acetyl‐β‐D‐glucosaminidase , and uric acid clearance . During treatment with enalapril  , renal plasma flow ( measured with 131l‐iodohippurate sodium ) and glomerular filtration rate increased by 12.1 % and 6.8 % . Changes in renal plasma flow correlated inversely with age and final mean arterial pressure and correlated positively with initial plasma renin activity of subjects . Except for an occasional idiosyncratic adverse reaction , enalapril is a safe and effective antihypertensive drug with the unique ability to increase renal function despite a fall in renal perfusion pressure
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .